Arch Therapeutics Issued Notice of Allowance for AC5 Surgical Hemostatic Device

Arch Therapeutics has announced that the U.S. Patent and Trademark Office has issued a notice of allowance related to the company’s AC5 surgical hemostatic device.

The broad-method-of-use patent covers technology for treating damaged extracellular matrix and leaky tight junctions.

The Framingham, Mass.-based company now has received patent allowances from the U.S., Japan, Europe, Canada, Israel, Australia, Hong Kong and China. — Anisa Jibrell